A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2013 by Dickson, Patricia I., M.D.
Sponsor:
Collaborators:
MPS I Intrathecal Research Collaborative
The Ryan Foundation for MPS Children
BioMarin Pharmaceutical
Rare Diseases Clinical Research Network
University of Minnesota - Clinical and Translational Science Institute
University of California, Los Angeles
Information provided by (Responsible Party):
Patricia I. Dickson, M.D., Dickson, Patricia I., M.D.
ClinicalTrials.gov Identifier:
NCT00852358
First received: February 25, 2009
Last updated: June 18, 2013
Last verified: June 2013
  Purpose

This is a 24-month study of the use of laronidase administered into the spinal fluid to treat cognitive decline in mucopolysaccharidosis I (MPS I). MPS I is a rare genetic condition due to deficiency of the enzyme alpha-l-iduronidase. Laronidase is the manufactured form of the enzyme alpha-l-iduronidase.

MPS I is a heterogeneous disease with several clinical phenotypes ranging from the most severe, Hurler syndrome, to the attenuated forms, Hurler-Scheie and Scheie. Although patients with milder forms of MPS I may not have grossly observable problems with cognition, these patients do have learning difficulties that are apparent in school and with neuropsychological testing. The goal of this study is to evaluate whether intrathecal recombinant human alpha-l-iduronidase (rhIDU) injections can stabilize or improve cognitive decline in individuals with MPS I.


Condition Intervention
Cognitive Decline
Mucopolysaccharidosis I
Hurler-Scheie Syndrome
Scheie Syndrome
Lysosomal Storage Disease
Drug: laronidase

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I

Resource links provided by NLM:


Further study details as provided by Dickson, Patricia I., M.D.:

Primary Outcome Measures:
  • The objective of this study is to assess the ability of intrathecal α-L-iduronidase to be administered safely [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The objective of this study is to assess the ability of intrathecal α-L-iduronidase to stabilize or reverse cognitive decline. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 16
Study Start Date: June 2009
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: intrathecal laronidase
The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
Drug: laronidase
For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Other Names:
  • Aldurazyme
  • recombinant human alpha-l-iduronidase
Control Group
During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
Drug: laronidase
For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
Other Names:
  • Aldurazyme
  • recombinant human alpha-l-iduronidase

Detailed Description:

This study is a 24-month open label, prospective, randomized trial in 16 MPS I patients age six years or older who have documented evidence of cognitive decline. The study will test the safety and efficacy of intrathecal recombinant human alpha-L iduronidase (rhIDU) to reduce or stabilize cognitive decline by assessing the subjects at baseline with neuropsychological, clinical, radiological, and biochemical evaluations and then monitoring the change in these parameters during a regimen of first monthly, then quarterly, intrathecal treatments with rhIDU. The clinical safety of the regimen will be assessed by monitoring of adverse events, cerebrospinal fluid (CSF) laboratory assessments, and clinical evaluations.

Subjects will be randomized to a treatment or a control group for 12 months, following which all subjects will receive 12 months of active treatment. During the first 12 months, the control group will receive similar study assessments but will be unblinded with no placebo administered. Subjects will have extensive baseline screening evaluations, after which subjects who were randomized to the treatment group will receive their first dose of intrathecal rhIDU. The enzyme will be administered via intrathecal injection at 1-3 month intervals throughout the 24-month study period. There will be a mid-study analysis after 12 months comparing changes in IQ and memory tests between controls and the treatment group. If pre-established criteria of improvement are met, the study will terminate at the 12 month point. If shown to be effective, intrathecal enzyme replacement therapy (ERT) would be the only treatment for cognitive decline in patients who do not qualify for and/or are unable to have hematopoietic stem cell transplantation.

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The presence of MPS I disease as documented by low α-L-iduronidase activity
  • Age six years or older.
  • The presence of acquired cognitive deficits as demonstrated by:

    1. A score of one standard deviation below mean on IQ testing or in one domain of neuropsychological function (language, memory, or non-verbal ability), OR
    2. Documented historical evidence of a decline of greater than one standard deviation on sequential testing, OR
    3. A score between 0.75 and 1 standard deviation below the mean, AND the cognitive deficit affects daily performance.
  • The decline in function is not explainable by other neurological or psychiatric factors.
  • Subject and/or guardian willing and able to provide written informed consent.
  • Negative urine pregnancy test at screening (non-sterile females of child-bearing potential only)
  • Currently using two acceptable methods of birth control as determined by the investigator and willing to continue to use acceptable birth control during their participation in the study (non-sterile females of child-bearing potential who are sexually active only)
  • Willing and able to comply with study procedures. For example, the subjects must be able to complete written and computer-based testing. The subjects must be able to lie still in the MRI scanner for at least 40 minutes without sedation.

Exclusion Criteria:

  • The subject has undergone hematopoietic stem cell transplantation
  • Recent initiation of intravenous Aldurazyme® therapy with less than 6 months of therapy. Subjects who have been receiving Aldurazyme® therapy for more than 6 months, and those who have never received Aldurazyme® therapy, will be allowed to enroll
  • Pregnant or lactating, or considering pregnancy
  • Receipt of an investigational drug or procedure within 30 days of enrollment
  • A condition, medical or other, that prevents participation in the study, including severe auditory or visual impairment, significant lumbar pathology, lumbar catheter, or recent major surgery within 6 weeks that would preclude their ability to participate.
  • Infusion reactions to intravenous Aldurazyme® therapy that require ongoing medical intervention, special prophylaxis or altered rate or dose of enzyme administration
  • The subject has a programmable VP shunt that is incompatible with the 3 Tesla MRI magnet and is unable or unwilling to undergo shunt revision to a MRI compatible device.
  • The subject has another contraindication for MRI, such as nonremovable metal in the body.
  • The subject has severely impaired spinal CSF flow, demonstrated by failure of appearance of 99mTechnetium-DTPA in the basal cisterns by 4 hours after intra-lumbar administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00852358

Contacts
Contact: Agnes Chen, MD 310-222-4160 ahchen@ucla.edu

Locations
United States, California
Children's Hospital & Research Center Oakland Recruiting
Oakland, California, United States, 94609-1809
Contact: Paul Harmatz, M.D.    510-428-3058    PHARMATZ@mail.cho.org   
Principal Investigator: Paul Harmatz, M.D.         
Los Angeles Biomedical Institute at Harbor-UCLA Recruiting
Torrance, California, United States, 90502
Contact: Agnes Chen, MD    310-222-4160    ahchen@ucla.edu   
Principal Investigator: Agnes Chen, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Elsa Shapiro, Ph.D.    612-625-1618    shapi004@umn.edu   
Principal Investigator: Elsa Shapiro, Ph.D.         
Sponsors and Collaborators
Patricia I. Dickson, M.D.
MPS I Intrathecal Research Collaborative
The Ryan Foundation for MPS Children
BioMarin Pharmaceutical
Rare Diseases Clinical Research Network
University of Minnesota - Clinical and Translational Science Institute
University of California, Los Angeles
Investigators
Principal Investigator: Agnes Chen, MD Los Angeles Biomedical Institute at Harbor-UCLA
Principal Investigator: Patricia I Dickson, MD Los Angeles Biomedical Institute at Harbor-UCLA
  More Information

No publications provided

Responsible Party: Patricia I. Dickson, M.D., Associate Professor of Pediatrics, Dickson, Patricia I., M.D.
ClinicalTrials.gov Identifier: NCT00852358     History of Changes
Other Study ID Numbers: MIRC-002, MIRC-002, IRB Project No. 13270-01, IND 104,354, U54NS065768
Study First Received: February 25, 2009
Last Updated: June 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Dickson, Patricia I., M.D.:
mucopolysaccharidosis
Hurler-Scheie
Scheie
laronidase
cognitive decline
central nervous system
enzyme replacement therapy
intrathecal
LA Biomed

Additional relevant MeSH terms:
Mucopolysaccharidosis I
Cognition Disorders
Lysosomal Storage Diseases
Mucopolysaccharidoses
Syndrome
Carbohydrate Metabolism, Inborn Errors
Connective Tissue Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Disease
Genetic Diseases, Inborn
Mental Disorders
Metabolic Diseases
Metabolism, Inborn Errors
Mucinoses
Pathologic Processes

ClinicalTrials.gov processed this record on October 23, 2014